Anti-cancer antibody developer Igenica has picked up $14m in Series C extension financing from all of its existing venture capital backers.
Third Rock Ventures, 5AM Ventures, OrbiMed and The Column Group all took part in the financing round for the company, which develops antibodies and antibody drug coagulates.
The Column Group managing partner David Goeddel, who is chairman of Igenica, said, “This financing reflects the enthusiasm of the investment syndicate for the compelling drug candidates and antibody-drug conjugate technology Igenica is developing.”
Two months ago biotech startup ImmunGene raised a $9m Series A round from Ally Bridge Group to advance its early-stage development products to IND-enabling studies.
The Thousand Oaks, California-based company is focused on developing antibody-cytokine fusion technology therapies to treat cancer.
Copyright © 2014 AltAssets